This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Toronto directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $608,175
Intravenous Ketamine versus Personalized Accelerated Brain Stimulation in Treatment-Resistant Depression: A Pilot Randomized Feasibility Trial of Rapid-Acting Treatments (IKARE-TRD)
CIHR · 2023 · Principal investigator
- $918,000
Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) and Intravenous Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
CIHR · 2021 · Co-investigator
Intravenous Ketamine versus Personalized Accelerated Brain Stimulation in Treatment-Resistant Depression: A Pilot Randomized Feasibility Trial of Rapid-Acting Treatments (IKARE-TRD)
Principal investigators: Bhat, Venkat; Dunlop, Katharine A; Kcomt, Andrew; Ladha, Karim; Lou, Wen-Yi W; Swainson, Jennifer N; Zhang, Yanbo
Keywords: Brain Stimulation; Iv Ketamine; Pilot Trial; Randomized Controlled Trial; Treatment-Resistant Depression
Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) and Intravenous Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Principal investigators: McIntyre, Roger S; Rosenblat, Joshua D
Keywords: Cognitive Behavioural Therapy; Glutamate; Ketamine; Major Depressive Disorder; Nmda Antagonist; Psychopharmacology; Randomized Clinical Trial; Rapid Treatments; Suicide; Treatment-Resistant Depression
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.